Antibodies that guard against COVID-19 can transfer from mothers to babies while in the womb, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian researchers published in the American Journal of Obstetrics and Gynecology.
Date Time
Share
Myovant Sciences and Pfizer Announce Publication in New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily
(GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced publication in the New England Journal of Medicine of the Phase 3 LIBERTY 1 and LIBERTY 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with uterine fibroids. As previously reported, both studies achieved the primary endpoint of response rates in menstrual blood loss in addition to six of the seven key secondary endpoints, while maintaining bone mineral density comparable to placebo as part of a well-tolerated safety profile over 24 weeks.
Study finds high COVID-19 infection rates in pregnant women
The COVID-19 infection rate among pregnant women was estimated to be 70% higher than in similarly aged adults in Washington state, according to a new study published today in
American Journal of Obstetrics and Gynecology. Other key findings include:
The study also showed that the number of COVID-19 infections in pregnant patients from nearly all communities of color in Washington was high. There was a twofold to fourfold higher prevalence of pregnant patients with COVID-19 infections from communities of color than expected based on the race-ethnicity distribution of pregnant women in Washington in 2018.
Computational Medicine - Moving from Uncertainty to Precision
Collaboration between Dell Med, Oden Institute, TACC, industry, government establishes Texas as a leader in computational medicine
Published on February 10, 2021 by Faith Singer-Villalobos
Individual choices in medicine carry a certain amount of uncertainty.
An innovative partnership at The University of Texas at Austin takes aim at medicine down to the individual level by applying state-of-the-art computation to medical care. Medicine in its essence is decision-making under uncertainty, decisions about tests and treatments, said Radek Bukowski, MD, PhD, professor and associate chair of Investigation and Discovery in the Department of Women s Health at Dell Medical School at UT Austin.
Innovative collaboration applies state-of-the-art computation to medical care
Individual choices in medicine carry a certain amount of uncertainty.
An innovative partnership at The University of Texas at Austin takes aim at medicine down to the individual level by applying state-of-the-art computation to medical care. Medicine in its essence is decision-making under uncertainty, decisions about tests and treatments, said Radek Bukowski, MD, PhD, professor and associate chair of Investigation and Discovery in the Department of Women s Health at Dell Medical School at UT Austin.
The human body and the healthcare system are complex systems made of a vast number of intensely interacting elements, he said. In such complex systems, there are many different pathways along which an outcome can occur. Our bodies are robust, but this also makes us very individualized, and the practice of medicine challenging. Everyone is made of different combinations of risk factors and protective cha